Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling
  • M&A / Deals

Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling

BioSpace

A trifecta of newly inked tech partnerships--from Eli Lilly, Bristol Myers Squibb and Incyte--exemplify the increasingly central role that AI is playing in drug development.

Read full story

pharminent May 21, 2026 (Last updated: May 21, 2026)

BioSpace

A trifecta of newly inked tech partnerships–from Eli Lilly, Bristol Myers Squibb and Incyte–exemplify the increasingly central role that AI is playing in drug development.

Read full story

Post navigation

Previous: BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication
Next: Lilly’s ‘triple G’ retatrutide aces crucial obesity trial

Related Stories

  • M&A / Deals

BioMarin spends up to $490m for Alesta’s bone disease candidate

pharminent August 19, 2026
  • M&A / Deals

J&J hands lymphoma bispecific CAR T back to AbelZeta

pharminent August 17, 2026
  • M&A / Deals

Novo Nordisk and AWS form AI partnership to speed drug discovery

pharminent August 17, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.